These discoveries have led to the development of specific IDH1/2-mutant inhibitors, such as ivosidenib [12] and enasidenib [13,14], which are successful examples of targeting cancer metabolism in patients with IDH1- or IDH2-mutated acute myeloid leukemia. Here, IDH1 is linked to cancer.